HBC Immunology is proud to announce that its prostate cancer treatment xenograft study with its lead peptide FT002a was completed successfully. This was done in combination with the standard-of-care hormonal-targeting therapies. The anti-tumor effect of oral FT002a was significantly enhanced by enzalutamide, the leading androgen-receptor inhibitor on the market (Xtandi (r)), in indolent and aggressive prostate cancer models.
The most common cancer diagnosed in men is prostate cancer. Advanced prostate cancer is incurable, even though it does not reduce life expectancy in most cases. The cornerstone treatment is hormone therapy. However, the tumors will eventually overcome this and grow and spread. The use of co-therapies can be a vital way to improve cancer treatment and increase tumor sensitivity.
Bomi Framaroze, CEO of HBCI, explains that cancer’s ability to manipulate iron metabolism is a key driver for tumor growth, spreading, and overcoming the treatment effects. Our lead peptide, FT002a, can potentially improve cancer treatment and patients’ overall health.
Cancer cells require higher levels of iron to grow and spread. FT002a also showed decreased biomarkers for free iron within prostate cancer cells. This validated its proposed mechanism of action.
These promising results and the inherent safety of peptidyl drugs mean that HBCI will be well positioned in Q4 of 2025 to submit an IND for its oral therapy for prostate cancer treatment..
Read for more at https://medicalguro.com/peshawar-faces-a-growing-threat-from-dengue
